RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+5.59%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$908M
AUM Growth
+$908M
(+6.2%)
Cap. Flow
+$37.5M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
29.34%
Holding
100
New
7
Increased
28
Reduced
31
Closed
12
Top Buys
| 1 |
Horizon Bancorp
HBNC
|
$26.2M |
| 2 |
HCA Healthcare
HCA
|
$18.4M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$9.08M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.72M |
| 5 |
STML
Stemline Therapeutics, Inc.
STML
|
$7.57M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$24.8M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
$14.8M |
| 3 |
AGN
Allergan plc
AGN
|
$13M |
| 4 |
Cigna
CI
|
$10M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
$9.17M |
Sector Composition
| 1 | Healthcare | 91.04% |
| 2 | Financials | 2.97% |
| 3 | Industrials | 0.36% |
| 4 | Technology | 0.08% |
| 5 | Energy | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$100B
| $34M | 3.74% | 185,232 +40,832 | +28% | +$7.49M |
|
2
Humana
HUM
$36.5B
| $27.9M | 3.07% | 105,000 +28,000 | +36% | +$7.43M |
|
3
Jazz Pharmaceuticals
JAZZ
$7.75B
| $26.7M | 2.94% | 187,171 | – | – |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $26.6M | 2.93% | 203,017 +66,551 | +49% | +$8.72M |
|
|
5
Horizon Bancorp
HBNC
$864M
| $26.2M | 2.88% | +1,087,656 | New | +$26.2M |
|
6
Nektar Therapeutics
NKTR
$568M
| $25.8M | 2.84% | 725,000 -9,445 | -1% | -$336K |
|
7
UnitedHealth
UNH
$281B
| $25.6M | 2.82% | 105,000 -18,400 | -15% | -$4.49M |
|
8
Elevance Health
ELV
$71.8B
| $25.4M | 2.8% | 90,000 +16,355 | +22% | +$4.62M |
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $24.2M | 2.67% | 92,900 +407 | +0.4% | +$106K |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $24.1M | 2.65% | 281,349 +49,800 | +22% | +$4.27M |
|
11
NovoCure
NVCR
$1.38B
| $23.1M | 2.55% | 365,899 -88,748 | -20% | -$5.61M |
|
12
Abbott
ABT
$231B
| $21.8M | 2.4% | 259,552 | – | – |
|
13
Becton Dickinson
BDX
$55.3B
| $20.2M | 2.22% | 80,000 +5,000 | +7% | +$1.26M |
|
14
Esperion Therapeutics
ESPR
$448M
| $19.2M | 2.11% | 412,093 -67,674 | -14% | -$3.15M |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $18.7M | 2.07% | 182,008 +54,915 | +43% | +$5.66M |
|
16
CVS Health
CVS
$92.8B
| $18.7M | 2.06% | 343,768 -10,100 | -3% | -$550K |
|
17
Iovance Biotherapeutics
IOVA
$807M
| $18.4M | 2.03% | 750,700 -128,900 | -15% | -$3.16M |
|
|
18
HCA Healthcare
HCA
$94.5B
| $18.4M | 2.03% | +136,164 | New | +$18.4M |
|
19
Glaukos
GKOS
$5.5B
| $17.8M | 1.96% | 235,911 +332 | +0.1% | +$25K |
|
20
Eli Lilly
LLY
$657B
| $17.7M | 1.95% | 160,000 +61,305 | +62% | +$6.79M |
|
21
Boston Scientific
BSX
$156B
| $16.7M | 1.84% | 387,908 +20,000 | +5% | +$860K |
|
22
Medtronic
MDT
$119B
| $15.9M | 1.75% | 162,883 -5,959 | -4% | -$580K |
|
23
FibroGen
FGEN
$47.8M
| $15.7M | 1.73% | 347,439 +157,948 | +83% | +$7.14M |
|
24
Centene
CNC
$14.3B
| $15.5M | 1.7% | 295,000 +95,000 | +48% | +$4.98M |
|
25
Bristol-Myers Squibb
BMY
$96B
| $15.3M | 1.69% | 338,386 +108,386 | +47% | +$4.92M |
|